Patents by Inventor Tong-Young Lee
Tong-Young Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230341406Abstract: The present invention is concerned with a protein oligomer comprising at least two NC-1 monomers of human collagen 18 or fragments of an NC-1 monomer of human collagen 18 for use in the treatment or prevention of an angiogenesis-related disease. The invention further pertains to a fusion protein comprising a NC-1 monomer of human collagen 18 and a Fc domain of an immunoglobulin. The invention also relates to a fusion protein comprising: a) an endostatin peptide or endostatin-derived peptide and b) the RGD motif and/or PHSRN motif of Fibronectin. The invention further relates to a kit comprising the protein oligomer or fusion proteins of the invention.Type: ApplicationFiled: October 14, 2022Publication date: October 26, 2023Applicant: Deutsches KrebsforschungszentrumInventors: Tong-Young LEE, Amir ABDOLLAHI, Kashi JAVAHERIAN
-
Patent number: 10370443Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.Type: GrantFiled: August 25, 2017Date of Patent: August 6, 2019Assignee: Fountain Biopharma Inc.Inventors: Tong-Young Lee, Han-Chung Wu, Tanny Chen Tsao, Willie Lin
-
Publication number: 20170362317Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.Type: ApplicationFiled: August 25, 2017Publication date: December 21, 2017Applicant: Fountain Biopharma Inc.Inventors: Tong-Young Lee, Han-Chung Wu, Tanny Chen Tsao, Willie Lin
-
Patent number: 9758580Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.Type: GrantFiled: December 31, 2015Date of Patent: September 12, 2017Assignee: Fountain Biopharma Inc.Inventors: Tong-Young Lee, Han-Chung Wu, Tanny Chen Tsao, Willie Lin
-
Publication number: 20160185851Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.Type: ApplicationFiled: December 31, 2015Publication date: June 30, 2016Applicant: Fountain Biopharma Inc.Inventors: Tong-Young Lee, Han-Chung Wu, Tanny Chen Tsao, Willie Lin
-
Patent number: 9234035Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.Type: GrantFiled: October 18, 2013Date of Patent: January 12, 2016Assignee: Fountain Biopharma Inc.Inventors: Tong-Young Lee, Han-Chung Wu, Tanny Chen Tsao, Willie Lin
-
Publication number: 20140302026Abstract: The present invention is concerned with a protein oligomer comprising at least two NC-1 monomers of human collagen 18 or fragments of an NC-1 monomer of human collagen 18 for use in the treatment or prevention of an angiogenesis-related disease. The invention further pertains to a fusion protein comprising a NC-1 monomer of human collagen 18 and a Fc domain of an immunoglobulin. The invention also relates to a fusion protein comprising: a) an endostatin peptide or endostatin-derived peptide and b) the RGD motif and/or PHSRN motif of Fibronectin. The invention further relates to a kit comprising the protein oligomer or fusion proteins of the invention.Type: ApplicationFiled: August 23, 2012Publication date: October 9, 2014Applicant: Deutsches KrebsforschungszentrumInventors: Tong-Young Lee, Amir Abdollahi, Kashi Javaherian
-
Publication number: 20140112935Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.Type: ApplicationFiled: October 18, 2013Publication date: April 24, 2014Applicant: Fountain Biopharma Inc.Inventors: Willie Lin, Tong-Young Lee, Han-Chung Wu, Tanny Chen Tsao
-
Patent number: 8088887Abstract: The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target neovasculature and were identified by in vivo phage display. One such peptide, SP5-52, recognized the neovasculature of multiple tumors in SCID mice, but did not target normal blood vessels. This peptide also binds to blood vessels of human lung cancer biopsy specimens. Liposomes comprising SP5-52 and doxorubicin enhanced the efficacy of the drug against multiple human cancer xenografts in SCID mice.Type: GrantFiled: April 13, 2007Date of Patent: January 3, 2012Assignees: Academia Sinica, National Taiwan UniversityInventors: Han-Chung Wu, Chin-Tarng Lin, Tong-Young Lee, Szu-Yao Kuo
-
Publication number: 20080193510Abstract: The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target neovasculature and were identified by in vivo phage display. One such peptide, SP5-52, recognized the neovasculature of multiple tumors in SCID mice, but did not target normal blood vessels. This peptide also binds to blood vessels of human lung cancer biopsy specimens. Liposomes comprising SP5-52 and doxorubicin enhanced the efficacy of the drug against multiple human cancer xenografts in SCID mice.Type: ApplicationFiled: April 13, 2007Publication date: August 14, 2008Inventors: Han-Chung Wu, Chin-Tarng Lin, Tong-Young Lee, Szu-Yao Kuo
-
Patent number: 7238665Abstract: The present invention provides a peptide marker targeting to nasopharyngeal carcinoma (NPC) cells and application thereof. The peptide binds specifically to the cell surface of NPC cells. After conjugated with liposome containing chemotherapeutic drugs, such peptides deliver chemotherapeutic drugs to the tumor cells specifically and destruct tumor cells without damaging normal tissues and organs. Furthermore, such peptide is applied as a detector in the development of NPC diagnosis kit.Type: GrantFiled: March 9, 2004Date of Patent: July 3, 2007Assignee: National Taiwan UniversityInventors: Han-Chung Wu, Chin-Tarng Lin, Tong-Young Lee
-
Publication number: 20050010036Abstract: The present invention provides a peptide marker targeting to nasopharyngeal carcinoma (NPC) cells and application thereof. The peptide binds specifically to the cell surface of NPC cells. After conjugated with liposome containing chemotherapeutic drugs, such peptides deliver chemotherapeutic drugs to the tumor cells specifically and destruct tumor cells without damaging normal tissues and organs. Furthermore, such peptide is applied as a detector in the development of NPC diagnosis kit.Type: ApplicationFiled: March 9, 2004Publication date: January 13, 2005Inventors: Han-Chung Wu, Chin-Tarng Lin, Tong-Young Lee
-
Patent number: 6646856Abstract: A static electricity removal apparatus capable of raising an alternating rate at which ions are generated according to the speed of an object requiring static electricity removal using a high-frequency high voltage AC voltage includes: at least one discharge electrode assembly having a plurality of needle-shaped electrodes aligned with each other, each needle-shaped electrode receiving the high-frequency high voltage AC voltage and generating ions using a corona discharge; a ground electrode for facilitating ion generation by the plurality of needle-shaped electrodes; a high-frequency high voltage generation unit connected to the at least one discharge electrode assembly, the voltage generation unit generating the high-frequency high voltage AC voltage outputted to the plurality of needle-shaped electrodes; and an ion blower adapted to blow ions from the plurality of needle-shaped electrodes to the object requiring static electricity removal.Type: GrantFiled: May 1, 2002Date of Patent: November 11, 2003Assignee: Samsung Electro-Mechanics Co., Ltd.Inventors: Tong Young Lee, Yeo Song Yun, Jae Hun Oh, Eui Kyeong Choi
-
Publication number: 20030007307Abstract: The present invention relates to a static electricity removal apparatus which is capable of raising an alternating rate at which ions are generated according to the speed of the charged objects using a high-frequency high AC voltage, resulting in an increase in a static electricity removing efficiency. The static electricity removal apparatus comprises at least one discharge electrode assembly including a plurality of needle-shaped electrodes aligned with each other, each of the needle-shaped electrodes generating ions using a corona discharge under the condition that it is provided with a high-frequency high AC voltage, a ground electrode for inducing ion generation by each of the needle-shaped electrodes, and a high-frequency high voltage generation unit connected to the discharge electrode assembly, the voltage generation unit generating the high-frequency high AC voltage to be provided to each of the needle-shaped electrodes of the discharge electrode assembly.Type: ApplicationFiled: May 1, 2002Publication date: January 9, 2003Applicant: Samsung Electro-Mechanics Co., Ltd.Inventors: Tong Young Lee, Yeo Song Yun, Jae Hun Oh, Eui Kyeong Choi